Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · VIYASH

VIYASH

HealthcarePharmaceuticals & Biotechnology₹10400 cr market cap
₹235.84 ▲ +0.1% today As of 19 Nov 2026
52-week low ₹179.8952-week high ₹294.15

-19.9% from the 52-week high · +31.0% above the low

SeQuent Scientific Ltd. manufactures and produces veterinary pharmaceuticals and specialty chemicals. The company is headquartered in Bangalore, Karnataka and currently employs 1,958 full-time employees. The company went IPO on 2016-03-10. The firm operates in the domains of animal health, in which it provides active pharmaceutical ingredient (APIs) and finished dosage formulations, and analytical services. The firm through its subsidiary, Alivira Animal Health Limited, offers APIs and formulations. Alivira Animal Health Limited has manufacturing facilities in five countries, including India. The Company’s subsidiary, Sequent Research Limited, is a contract research organization, which is engaged in analytical and biological analytical services to support the API, pharmaceutical, personal care and nutraceutical companies. Sequent Research Limited provides complete analytical solutions, including method validation, stability, microbiology for APIs and finished products in a variety of dosage forms as per pharmacopeial monographs, customer-developed methods or in-house method development.

The short version. VIYASH reported revenue of ₹988 crore for Sep 2026, up 133.0% from a year earlier. Net profit was ₹76 crore (up 406.7% year on year). Return on equity was 6.1% in Mar 2026. Promoter holding was 49.24% in Sep 2026, down 3.37 points over 8 quarters.

1 · The price

How has the stock traded?

VIYASH trades 19.9% below its 52-week high and 31.0% above its 52-week low.

Change over period: —

1M+6.6%
3M-13.2%
6M-6.4%
1Y—

2 · The business

Is it growing?

Sales, year on year+133.0%

Sep 2026 revenue of ₹988 cr.

Profit, year on year+406.7%

Sep 2026 net profit of ₹76 cr.

Net margin7.7%

4.2 pts higher than a year earlier.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue988946920858424441402391
Net profit76665238151493
Net margin %7.77.05.74.53.53.22.30.9
EPS (₹)1.721.511.190.880.590.570.370.14

Annual

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue34201551137014211413136211791039
Net profit17722-36-12141957049
Net margin %5.21.4-2.6-8.52.97.05.94.7
EPS (₹)4.060.87-1.44-4.861.663.842.811.97

3 · The quality

How well does it turn capital into profit?

Return on equity was 6.1% in Mar 2026; debt to equity is 0.15.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %6.13.1-5.5-17.3
Return on capital %11.49.6-0.7-10.2
EBITDA margin %18.810.94.0-3.2
Net margin %5.11.4-2.6-8.5

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR34.4%20.4%
Profit CAGR—13.2%
Debt to equity0.15
Interest cover6.0x
Current ratio2.38
P/E ratio45.9

4 · The owners

Who holds it, and are they adding?

Promoter holding49.24%

Down 3.37 pts over 8 quarters.

Foreign institutions2.6%

Down 3.5 pts over 8 quarters.

Domestic institutions8.3%

Down 3.72 pts over 8 quarters.

Mutual fund schemes28

+4 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter52.6152.6152.6152.3361.4161.3161.3149.24-3.37
FII6.16.056.155.913.162.944.52.6-3.5
DII12.0212.8212.9912.917.367.993.758.3-3.72
Public29.1128.3628.128.6927.9727.6730.3439.76+10.65

Mutual fund holdings · Oct 2026

28 schemes hold this stock

24 the month before.

  • Kotak Special Opportunities Fund2.14% of NAV
  • Kotak Manufacture In India Fund1.53% of NAV
  • Kotak Healthcare Fund1.52% of NAV
  • UTI - Healthcare Fund1.36% of NAV
  • Kotak Consumption Fund1.35% of NAV
  • Kotak ELSS Tax Saver Fund1.29% of NAV
  • Kotak MNC Fund1.28% of NAV
  • EDELWEISS SMALL CAP FUND1.18% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for VIYASH are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about VIYASH

What is the VIYASH share price?

VIYASH (VIYASH) last closed at ₹235.84, up 0.1% on the day. Its 52-week range is ₹179.89 to ₹294.15.

What is the market cap of VIYASH?

VIYASH has a market capitalisation of about ₹10,400 crore. Its price-to-earnings ratio is 45.9.

How are VIYASH's latest results?

VIYASH reported revenue of ₹988 crore for Sep 2026, up 133.0% from a year earlier. Net profit was ₹76 crore (up 406.7% year on year). Return on equity was 6.1% in Mar 2026. Promoter holding was 49.24% in Sep 2026, down 3.37 points over 8 quarters.

Who owns VIYASH?

As of Sep 2026, shareholding was: Promoter 49.24%, FII 2.6%, DII 8.3%, Public 39.76%.

How many mutual funds hold VIYASH?

28 mutual fund schemes held VIYASH in October 2026. That compares with 24 the month before.

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.